Skip to main content

Nyxoah SA

corporate_fare Company Profile

Nyxoah SA

NYXH·NASDAQ·Industrial Applications And Services·CIK 0001857190

Nyxoah SA is a medical technology company that develops and commercializes solutions for Obstructive Sleep Apnea (OSA). The company's primary product is the Genio system, a hypoglossal neurostimulation (HGNS) therapy designed for moderate to severe OSA. This system is implanted through a single-incision procedure and is CE-Marked and FDA approved. OSA is a common sleep-disordered breathing condition linked to increased mortality risk and conditions such as cardiovascular diseases, depression, and stroke. The Genio system is a HGNS device that treats OSA by providing bilateral stimulation to maintain upper airway patency, reducing obstructive breathing events during sleep. Nyxoah SA began generating revenue from Genio system sales in Europe in July 2020. On August 8, 2025, the FDA approved the Genio system for adult patients with moderate to severe OSA, specifically those with an Apnea-Hypopnea Index (AHI) of greater than or equal to 15 and less than or equal to 65. Sales of the Genio system in the U.S. commenced in September 2025. Approximately 425 million people globally between the ages of 30 and 69 suffer from moderate to severe OSA. In Nyxoah SA's initial target markets in Europe, an estimated 23.8 million individuals have moderate to severe OSA.

Nyxoah SA (NASDAQ:NYXH) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 22 items for NYXH at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Nyxoah Expands Belgian Manufacturing Capacity to Support Global Growth
  • Nyxoah Reports Strong Q4 & FY2025 Revenue Growth, Positive Q1 2026 Guidance, and Successful U.S. Launch

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$90.08M
Diluted EPS
-$2.36
Op. Cash Flow
-$68.98M
Free Cash Flow
-$69.78M
Gross Profit
$6.33M
Operating Income
-$83.48M
Cash & Equivalents
$7.87M
Debt / Equity
0.00×
Shares Outstanding
43.03M sh
Source: 20-F · filed 2026-03-26 · accession 0001104659-26-035161

Insider Transactions

NYXH files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

$0.805
52-week range · as of 2026-11-05 $0.80 – $5.92
Market cap
$81.98M
Volume
97.5K (0.4× avg)
3-mo avg 223.7K
Live data · 2026-11-22 13:02 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NYXH - Filings & News (Page 2)

NYXH
Jan 30, 2026, 5:15 PM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.75
Real-time Price: $0.805 info
Change: -$3.95 (-83%) info
Market Cap: $81.981M info
NYXH
Jan 14, 2026, 4:05 PM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $5.12
Real-time Price: $0.805 info
Change: -$4.32 (-84%) info
Market Cap: $81.981M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets